Skip to content

A randomized controlled trial for local application of insulin-like growth factor 1 using gelatin hydrogels on patients with sudden sensorineural hearing loss

A randomized controlled trial for local application of insulin-like growth factor 1 using gelatin hydrogels on patients with sudden sensorineural hearing loss - A randomized controlled study of local IGF1 treatment for sudden deafness

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000004366
Enrollment
120
Registered
2010-11-30
Start date
2011-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sudden sensorineural hearing loss

Interventions

The gelatin hydrogels immersed with an IGF1 solution are placed into the round window niche in the middle ear. Intratympanic injections of dexamethasone (four times within seven days)

Sponsors

Graduate School of Medicine, Kyoto University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Subjects are patients with sudden sensorineural hearing loss, (1) who are diagnosed as definite or probable for the criteria for the diagnosis of idiopathic sudden sensorineural hearing loss (determined by the sudden deafness research committee of the Japanese Ministry of Health,Labour and Welfare in 1973). Subjects satisfy the following conditions; (2) presenting the abnormality in evoked otoacoustic emission, (3) determined as no recovery or slight recovery by the criteria for hearing improvement after systemic steroid application for more than seven days, (4) diagnosed within 25 days after the onset, (5) age is 20 years or over, (6) possible to come to outpatient clinic and (7) give their informed consent to participate in the trial.

Exclusion criteria

Exclusion criteria: The exclusion criteria are as follows; (1) presenting active chronic otitis media, acute otitis media, otitis media with effusion or dysfunction of the auditory tube, (2) medicated anti-coagulation drugs, (3) presenting following comorbidities; severe liver dysfunction, uncontrolled diabetes, pituitary or adrenal dysfunction, severe systemic illness with an expected life, (4) presenting following past histories; allergy for gelatin, drugs associated with the treatments in this trial, alcohol or drug dependence within 1 year, (5) presenting malignant tumors, (6) pregnant or lactating women, (7) individuals who are diagnosed as inappropriate for the trial.

Design outcomes

Primary

MeasureTime frame
The primary outcome measure was the proportion of patients showing hearing improvement, which was defined as better than slight recovery according to the following criteria 12 weeks after the treatment. The criteria for hearing improvement, which was determined by the sudden deafness research committee of the Japanese Ministry of Health, Labour and Welfare in 1984, is used in this study. Complete recovery is defined as recovery of a hearing level within 20 dB at all five frequencies tested: 0.25, 0.5, 1.0, 2.0 and 4.0 kHz or recovery to the same level as the opposite side. Marked recovery is defined as more than 30 dB recovery in the mean hearing level at the five frequencies tested. Slight recovery is defined as recovery of 10-29 dB in the mean hearing level at the five frequencies tested. No recovery is defined as less recovery than 10 dB in the mean hearing level at the five frequencies tested. In this study, hearing improvement is defined as better than slight recovery according to the criteria described above.

Secondary

MeasureTime frame
The secondary outcome measures were the proportion of patients showing hearing improvement 16 weeks after the test treatment and the incidence of adverse events during the observation period.

Countries

Japan

Contacts

Public ContactTakayuki Nakagawa

Graduate School of Medicine, Kyoto University Department of Otolaryngology, Head and Neck Surgery

tnakagawa@ent.kuhp.kyoto-u.ac.jp075-751-3346

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026